Efficacy of nanoparticle albumin-bound paclitaxel on advanced esophageal cancer

Objective To evaluate the clinical efficacy and safety of nanoparticle albumin-bound paclitaxel (Nab-P) in combination with cisplatin, Gio or bevacizumab in the treatment of advanced esophageal cancer. Methods Fifty-eight patients with advanced esophageal cancer in Chinese PLA General Hospital from January 2014 to October 2015 were included in this study. Patients in control group (n=30) were treated with traditional Paclitaxel and patients in experimental group (n=28) were treated with Nab-P (270 mg/m², d1, d8) based chemotherapy. The median age of patients in experimental group was 63 years old (ranging from 47 to 77 years old), with 27 males and 1 female. The median age of patients in control group was 65 years old (ranging from 49 to 81 years old), with 26 males and 4 females. There were no statistically significant differences in baseline data between patients in two groups (P> 0.05). Efficacy was evaluated every two cycles and adverse effects were evaluated every cycle. Results In control group, 7 patients achieved partial response (PR), 15 patients had stable disease (SD), 8 patients had progressive disease (PR) with the median progression-free survival of 4 months. In experimental group, 15 patients achieved PR, 10 patients had SD, 3 patients had PD with the median progression-free survival of 5 months. The efficacy of two treatment regimes had significant difference (P< 0.05). The adverse events in two groups were mainly hematologic toxicity, hair loss and peripheral neurotoxicity of I-II degree. Conclusion Nab-P plus cisplatin, Gio or bevacizumab shows favorable efficacy and less side effects, which can be an effective therapy for patients with advanced esophageal cancer.